(49 days)
WelchAllyn Master Elite Stethoscope, WelchAllyn Meditron Analyzer (K110704)
Unknown
The summary mentions a "Diagnostic Heart Murmur Algorithm" and "analyzing these signals" to distinguish between normal and pathological murmurs. While this suggests algorithmic processing, it doesn't explicitly state whether AI or ML techniques are used in this algorithm. The lack of mention of AI, DNN, or ML in the dedicated section further contributes to the uncertainty.
No
The device is described as a "decision support device" intended to assist clinicians in analyzing cardiac sounds and electrical signals for the identification and classification of suspected murmurs. It explicitly states it is "not intended to be a diagnostic device" and "does not supersede the judgment of the clinician." It aids in evaluation but does not provide therapy or treatment.
No
Explanation: The "Intended Use / Indications for Use" section explicitly states, "CardioSleeve is not intended to be a diagnostic device."
No
The device description explicitly states that the complete system comprises a "stethoscope front-end recorder device with integrated ECG to acquire the acoustic and electrical heart signals," which is a hardware component.
Based on the provided text, the CardioSleeve System is not an In Vitro Diagnostic (IVD) device.
Here's why:
- Intended Use: The intended use explicitly states that the device is a "decision support device" and is "not intended to be a diagnostic device." It is designed to assist clinicians in analyzing cardiac sounds and electrical signals, but the final diagnosis is made by the clinician.
- Nature of the Signals: The device analyzes acoustic signals (heart sounds) and electrical signals (ECG). IVD devices typically analyze samples taken from the body, such as blood, urine, or tissue.
- Clinical Setting: The device is used directly on the patient in a clinical setting, not in a laboratory setting for testing samples.
Therefore, the CardioSleeve System falls under the category of a medical device that provides information to aid in diagnosis, but it is not an IVD.
N/A
Intended Use / Indications for Use
The CardioSleeve System consisting of the CardioSleeve Front-End stethoscope with integrated ECG device. mobile heart sound and ECG recording application and the remote diagnostic heart murmur software is a decision support device intended to be used on a single patient to assist the qualified clinician in analyzing cardiac sounds and electrical signals for the identification and classification including of suspected murmurs. It is used to distinguish between normal/physiological and pathological heart murmurs by recording the acoustic signal of the heart and the ECG signal simultaneously and analyzing these signals. The acoustic heart signal is analyzed to identify specific heart sounds that may be present. Identified sounds include S1, S2, and suspected murmurs.
CardioSleeve indicates whether or not a recorded heart sound contains a suspected heart murmur. The device must be used in a clinical setting by trained personnel with the prescribed accessories and all relevant patient information must be taken into consideration before a diagnosis is made.
The interpretations of heart sounds offered by the CardioSleeve device are only significant when used in conjunction with physician over-read as well as consideration of all other relevant patient data.
CardioSleeve is not intended to be a diagnostic device. It does not supersede the judgment of the clinician. The device is intended to aid the physician in the evaluation of heart sounds. The clinicians are responsible for reviewing and interpreting the results, along with the auscultatory findings and medical history, when making a referral decision.
Product codes
DQD, DQC
Device Description
The CardioSleeve with Diagnostic Heart Murmur Application, (application identical to the FDA cleared Sensi with Diagnostic Heart Murmur Software-K110704), is a decision support device intended to acquire, record, and analyze heart sounds. It is used to distinguish between normal and pathological heart murmurs by recording the acoustic signal of the heart and the ECG signal simultaneously and analyzing these signals, and to acquire, record and display 3 Lead ECG signals for diagnostic support.
The complete system comprises of: a) Diagnostic Heart Murmur Algorithm (algorithm identical to the FDA cleared Diagnostic Heart Murmur Algorithm in K110704), that runs on a hosted server environment with Linux operating system, b) a mobile device software application that captures patient data, displays patient data and instructions for use and c) a stethoscope front-end recorder device with integrated ECG to acquire the acoustic and electrical heart signals. The CardioSleeve Front-end recorder device will interface via Bluetooth with the clinician's hand held mobile device.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Heart
Indicated Patient Age Range
Not Found
Intended User / Care Setting
qualified clinician, clinical setting
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Comparative study between FDA approved CardioSleeve and Sensi system: CardioSleeve and Sensi achieve comparable accuracy of 70.8%.
Design verification of a CAA algorithm: Specificity of 94% and Sensitivity of 91%.
Validate algorithms used to distinguish between functional and pathological heart murmurs in the pediatric population: 1568 heart sounds were accepted to meet the criteria of good quality and match the recorded pathological conditions.
Verification of the acoustic performance of the CardioSleeve front-end: The CardioSleeve Front-End perform favorably, in responding to heart sound frequency of 20hz to 500hz.
Key Metrics
Accuracy: 70.8%
Specificity: 94%
Sensitivity: 91%
Predicate Device(s)
Reference Device(s)
WelchAllyn Master Elite Stethoscope, WelchAllyn Meditron Analyzer (K110704)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 870.1875 Stethoscope.
(a)
Manual stethoscope —(1)Identification. A manual stethoscope is a mechanical device used to project the sounds associated with the heart, arteries, and veins and other internal organs.(2)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 870.9.(b)
Electronic stethoscope —(1)Identification. An electronic stethoscope is an electrically amplified device used to project the sounds associated with the heart, arteries, and veins and other internal organs.(2)
Classification. Class II (special controls). The device, when it is a lung sound monitor, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 870.9.
0
510 (k) Summary 807.92(c)
JUN 2 4 2013
SPONSOR
Company Name: Company Address:
807.92(a)(1) Rijuven Corporation 624 Whispering Pines Drive Pittsburgh PA, 15238 +1 (301) 335-9163 +1 (412) 967-9393 Evens Augustin March 2, 2013
Telephone:
Fax:
Contact Person Summary Preparation Date:
DEVICE NAME
807.92(a)(2)
Trade Name: Common/Usual Name:
Classification Name: Regulation Number: Product Code: Device Class:
CardioSleeve Electronic Stethoscope / Heart Sound Analyzer Electronic Stethoscope; Phonocardiograph 21 CFR 870.1875, 870.2390 DQD, DQC Class II
PREDICATE DEVICE
807.92(a)(3)
Legally Marketed Equivalent Device
| Company | Product | 510(k) # |
|---|---|---|
| Diacoustic Medical | ||
| Devices (Pty) Ltd | Sensi with Diagnostic | |
| Heart Murmur Software | K110704 |
1
DEVICE DESCRIPTION 807.92(a)(4)
The CardioSleeve with Diagnostic Heart Murmur Application, (application identical to the FDA cleared Sensi with Diagnostic Heart Murmur Software-K110704), is a decision support device intended to acquire, record, and analyze heart sounds. It is used to distinguish between normal and pathological heart murmurs by recording the acoustic signal of the heart and the ECG signal simultaneously and analyzing these signals, and to acquire, record and display 3 Lead ECG signals for diagnostic support.
The complete system comprises of: a) Diagnostic Heart Murmur Algorithm (algorithm identical to the FDA cleared Diagnostic Heart Murmur Algorithm in K110704), that runs on a hosted server environment with Linux operating system, b) a mobile device software application that captures patient data, displays patient data and instructions for use and c) a stethoscope front-end recorder device with integrated ECG to acquire the acoustic and electrical heart signals. The CardioSleeve Front-end recorder device will interface via Bluetooth with the clinician's hand held mobile device.
DEVICE INDICATIONS FOR USE 807.92(a)(5)
The CardioSleeve System consisting of the CardioSleeve Front-End stethoscope with integrated ECG device, mobile heart sound and ECG recording application and the remote diagnostic heart murmur software is a decision support device intended to be used on a single patient to assist the qualified clinician in analyzing cardiac sounds and electrical signals for the identification and classification including of suspected murmurs. It is used to distinguish between normal/physiological and pathological heart murmurs by recording the acoustic signal of the heart and the ECG signal simultaneously and analyzing these signals. The acoustic heart signal is analyzed to identify specific heart sounds that mav be present. Identified sounds include S1, S2, and suspected murmurs.
CardioSleeve indicates whether or not a recorded heart sound contains a suspected heart murmur. The device must be used in a clinical setting by trained personnel with the prescribed accessories and all relevant patient information must be taken into consideration before a diagnosis is made.
The interpretations of heart sounds offered by the CardioSleeve device are only significant when used in conjunction with physician over-read as well as consideration of all other relevant patient data.
CardioSleeve is not intended to be a diagnostic device. It does not supersede the judgment of the clinician. The device is intended to aid the physician in the evaluation of heart sounds. The clinicians are responsible for reviewing and interpreting the results, along with the auscultatory findings and medical history. when making a referral decision.
Caution: Federal (USA) law restricts this device to sale by or on the order of a clinician
2
COMPARISON OF TECHNICAL CHARACTERISTICS 807.92(a)(6)
The CardioSleeve device features were directly compared with the FDA cleared Sensi with Diagnostic Heart Murmur Software, WelchAllyn Master Elite Stethoscope and the WelchAllyn Meditron Analyzer (K110704).
Synopsis of the comparison analysis:
-
. Intended Use:
CardioSleeve and Sensi with Diagnostic Heart Murmur Software do have an equivalent intended use. -
. Indications for Use:
CardioSleeve and Sensi with Diagnostic Heart Murmur Software do have identical indications for use. -
. Composition
CardioSleeve and Sensi with Diagnostic Heart Murmur Software compromises equivalent functions system composition. -
. Physical Properties
CardioSleeve with Front-end unit and Diagnostic Heart Murmur Software, and Sensi with Diagnostic Heart Murmur Software, the WelchAllyn Master Elite Stethoscope and the WelchAllyn Meditron Analyzer share equivalent physical characteristics (K110704). -
. Technology Characteristics
CardioSleeve consists of a front-end recorder device with a Bluetooth interface connected to a standard acoustic stethoscope recording both the acoustic heart sound and/or ECG signal. The Sensi consists of an electronic stethoscope and ECG recorder connecting to a PC by means of a USB interface for recording of acoustical body sounds.
CardioSleeve and Sensi with Diagnostic Heart Murmur Software are using identical heart murmur analysis algorithm.
CardioSleeve and Sensi with Diagnostic Heart Murmur Software are using equivalent user interface properties.
SAFETY AND EFFECTIVENESS
807.92(b)
A comprehensive list of verification and validation testing was performed in accordance to Rijuven's Design Control procedures.
Software validation was performed for all aspects of the CardioSleeve System and Software. The graphical user interface and usability were compared to the predicate devices.
Validation of the CardioSleeve was performed to ensure that the CardioSleeve system consistently fulfills its intended use and the needs of the user. A clinical software validation was performed to insure the performance of the software algorithm.
3
| 1 | Biocompatibility Testing | CardioSleeve material presented no
issues of biocompatibility |
|---|---------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2 | Electrical Safety Testing | The CardioSleeve meets the
requirements of IEC 60601-1: 2005 +
CORR. 1 (2006) + CORR. 2 (2007). |
| 3 | Feasibility & Usability Study | Intended users performed usability
validation within real life clinical
settings.
On average all users scored the
usability of the CardioSleeve Software
more than 4 out of 5. |
| 4 | Comparative study between
FDA approved CardioSleeve
and Sensi system | CardioSleeve and Sensi achieve
comparable accuracy of 70.8% |
| 5 | Design verification of a CAA
algorithm | Specificity of 94% and Sensitivity of
91% |
| 6 | Validate algorithms used to
distinguish between functional
and pathological heart murmurs
in the pediatric population. | 1568 heart sounds were accepted to
meet the criteria of good quality and
match the recorded pathological
conditions |
| 7 | Verification of the acoustic
performance of the
CardioSleeve front-end | The CardioSleeve Front-End perform
favorably, in responding to heart
sound frequency of 20hz to 500hz |
CONCLUSION
807.92(b)(3)
Based upon the indications for use, technology characteristics and safety and performance testing, it is the conclusion of Rijuven that the CardioSleeve device consisting of the CardioSleeve Front-End stethoscope and ECG device, mobile heart sound recording application and the remote diagnostic heart murmur software is as safe and effective as the predicate devices and raises no new issues of safety and effectiveness.
4
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" around the perimeter. Inside the circle is a stylized symbol that resembles a person with outstretched arms.
June 24, 2013
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-002
Rijuven Corp Mr. E.J. Smith Regulatory Consultant 1468 Harwell Ave. Crofton, MD 21114 US
Re: K131287
Trade/Device Name: Cardiosleeve Regulation Number: 21 CFR 870.1875 Regulation Name: Electronic Stethoscope / Heart Sound Analyzer Regulatory Class: Class II Product Code: DQD, DQC Dated: May 9, 2013 Received: May 9, 2013
Dear Mr. E.J. Smith:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must
5
Page 2 - Mr. E.J. Smith
comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fdagov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, Misbranding by reference to premarket notification (21CFR Part 807.97), For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportalProblem/default.htmfor the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Bram D. Zuckerman -S
Bram D. Zuckerman, Ph.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
6
Indications for Use
510(k) Number (if known):
Device Name: CardioSleeve
Indications For Use:
The CardioSleeve System consisting of the CardioSleeve Front-End stethoscope with integrated ECG device. mobile heart sound and ECG recording application and the remote diagnostic heart murmur software is a decision support device intended to be used on a single patient to assist the qualified clinician in analyzing cardiac sounds and electrical signals for the identification and classification including of suspected murmurs. It is used to distinguish between normal/physiological and pathological heart murmurs by recording the acoustic signal of the heart and the ECG signal simultaneously and analyzing these signals. The acoustic heart signal is analyzed to identify specific heart sounds that may be present. Identified sounds include S1, S2, and suspected murmurs.
CardioSleeve indicates whether or not a recorded heart sound contains a suspected heart murmur. The device must be used in a clinical setting by trained personnel with the prescribed accessories and all relevant patient information must be taken into consideration before a diagnosis is made.
The interpretations of heart sounds offered by the CardioSleeve device are only significant when used in conjunction with physician over-read as well as consideration of all other relevant patient data.
CardioSleeve is not intended to be a diagnostic device. It does not supersede the judgment of the clinician. The device is intended to aid the physician in the evaluation of heart sounds. The clinicians are responsible for reviewing and interpreting the results, along with the auscultatory findings and medical history, when making a referral decision.
Caution: Federal (USA) law restricts this device to sale by or on the order of a clinician
Prescription Use X
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(Part 21 CFR 801 Subpart D)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Bram D. Zuckerman 2013.06.24 16:58:04 -